Statin Mechanisms in Parkinson's Disease Pathogenesis

Statins, inhibitors of the enzyme HMG-CoA reductase, have been widely prescribed for their cholesterol‐lowering effects, yet mounting evidence indicates they may exert multiple neuroprotective actions relevant to Parkinson’s disease (PD). By reducing de novo cholesterol synthesis in the brain, statins alter membrane lipid raft composition and thereby influence the aggregation and cell-to-cell propagation of α-synuclein, a key driver of dopaminergic neuron degeneration. Beyond lipid modulation, statins display anti-inflammatory properties through suppression of microglial activation and downregulation of pro-inflammatory cytokines. They also attenuate oxidative stress by inhibiting the NADPH oxidase/p38 MAPK pathway and by upregulating endogenous antioxidant proteins, thereby preserving mitochondrial function in vulnerable nigrostriatal neurons. Moreover, statins enhance autophagic clearance of misfolded proteins and stabilise the blood–brain barrier, potentially slowing the spread of pathology. Collectively, these multifaceted mechanisms suggest that statins could modify disease progression in PD, offering a rationale for repurposing these agents in clinical trials aimed at slowing motor and non-motor decline.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Statin Mechanisms in Parkinson's Disease Pathogenesis publication trend

The graph below shows the total number of articles in statin mechanisms in parkinson's disease pathogenesis across all publications each year (not limited to Nature Index journals).

Technical terms

α-synuclein: presynaptic neuronal protein prone to misfolding and aggregation, forming Lewy bodies in PD.

HMG-CoA reductase: rate-limiting enzyme in the mevalonate pathway of cholesterol synthesis, inhibited by statins.

Blood–brain barrier: specialised endothelial interface that regulates molecular and cellular traffic between blood and the central nervous system.

NADPH oxidase: enzyme complex that generates reactive oxygen species and contributes to oxidative stress in neurons.

MAPK pathway: mitogen-activated protein kinase cascade that mediates cellular responses to stress and inflammation.

References

1. Statins suppress cell-to-cell propagation of α-synuclein by lowering cholesterol. Cell Death & Disease (2023).
2. Simvastatin Inhibits Activation of NADPH Oxidase/p38 MAPK Pathway and Enhances Expression of Antioxidant Protein in Parkinson Disease Models. Frontiers in Molecular Neuroscience (2018).
3. Simvastatin Prevents Dopaminergic Neurodegeneration in Experimental Parkinsonian Models: The Association with Anti-Inflammatory Responses. PLOS ONE (2011).
4. Statin Use and the Risk of Parkinson's Disease: An Updated Meta-Analysis. PLOS ONE (2016).